Fortress Biotech Inc (NASDAQ:FBIO)’s traded shares stood at 0.83 million during the last session, with the company’s beta value hitting 1.68. At the close of trading, the stock’s price was $2.05, to imply a decrease of -0.24% or -$0.01 in intraday trading. The FBIO share’s 52-week high remains $4.43, putting it -116.1% down since that peak but still an impressive 33.66% since price per share fell to its 52-week low of $1.36. The company has a valuation of $56.59M, with an average of 0.74 million shares in intraday trading volume over the past 10 days and average of 674.94K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Fortress Biotech Inc (FBIO), translating to a mean rating of 1.00. Of 3 analyst(s) looking at the stock, 0 analyst(s) give FBIO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 1 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.75.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fortress Biotech Inc (NASDAQ:FBIO) trade information
After registering a -0.24% downside in the last session, Fortress Biotech Inc (FBIO) has traded red over the past five days. The 5-day price performance for the stock is -3.76%, and 16.48% over 30 days. With these gigs, the year-to-date price performance is -31.89%. Short interest in Fortress Biotech Inc (NASDAQ:FBIO) saw shorts transact 2.62 million shares and set a 4.57 days time to cover.
Fortress Biotech Inc (FBIO) estimates and forecasts
Looking at statistics comparing Fortress Biotech Inc share performance against respective industry, we note that the company has outperformed competitors. Fortress Biotech Inc (FBIO) shares are 13.89% up over the last 6 months, with its year-to-date growth rate higher than industry average at 61.28% against 17.50%. The rating firms project that company’s revenue will shrink -31.22% compared to the previous financial year.
Revenue forecast for the current quarter as set by 2 analysts is 15.58M.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 22.28% for the past 5-year period. While 2024 is set for a 58.60% return in earnings, projections for the next 5 years are at 25.50% annually.
FBIO Dividends
Fortress Biotech Inc has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Fortress Biotech Inc (NASDAQ:FBIO)’s Major holders
Fortress Biotech Inc insiders hold 21.21% of total outstanding shares, with institutional holders owning 15.78% of the shares at 20.03% float percentage. In total, 15.78% institutions holds shares in the company, led by B. RILEY WEALTH ADVISORS, INC.
